Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CFAP298-TCP10L readthrough is a fusion gene formed by the transcriptional continuation from the CFAP298 (C21orf59) gene into the adjacent TCP10L gene on chromosome 21. Readthrough transcripts may encode a fusion protein containing sequences from both parental gene products[2][8][9]. The precise biological function and disease relevance of the fusion protein remain unknown; it is not currently considered a drug target or biologically characterized protein. The parent genes are involved in ciliary function and assembly, with associated diseases including primary ciliary dyskinesia and heterotaxy, but evidence for involvement of the fusion gene in these conditions is lacking[2][3]. Alternative gene symbols and names reflect its hybrid nature and include those of both parental genes and long intergenic non-coding RNAs[2][8][9]. Existing protein databases annotate it as a protein coding locus, but further experimental validation and functional characterization are needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CFAP298-TCP10L readthrough (CFAP298-TCP10L).